

Phase	Trial ID	Status	Prime	Boost 1	Boost 2	Boost 3	Strategy	Location
II	HVTN 117 VA C89220HPX200 4	Ongoing	Ad26.Mos.HIV Trivalent	Ad26.Mos4.HIV	gp140 C		Viral Vector - Adeno, Viral Vector - Adeno, Viral Vector - Adeno	Rwanda
IIb	HVTN 704 AMP	Ongoing	VRC-HIVMAB0 60-00-AB				Passive Immunization	USA, Peru, Brazil
I	01-I-0079	Completed	VRC4302				DNA	USA
I	04/400-003-04	Completed	APL 400-003 GENEVAX-HIV				DNA	USA
I	10-1074	Ongoing	10-1074				Passive Immunization	Germany, USA
I	87 I-114	Completed	gp160 Vaccine (Immuno-AG)				Protein	USA
I	96-I-0050	Completed	APL 400-003 GENEVAX-HIV				DNA	USA
I/II	ACTG 326; PACTG 326	Completed	ALVAC vCP1452	AIDSVAX B/B			Viral Vector - Pox, Protein	USA
I	Ad26.ENVA.01	Completed	Ad26.EnvA-01				Viral Vector - Adeno	USA
I	Ad26.ENVA.01 Mucosal/IPCAV D003	Ongoing	Ad26.EnvA-01				Viral Vector - Adeno	USA
I	Ad5HVR48.EN VA.01	Ongoing	Ad5HVR48.EN VA.01				Viral Vector - Adeno	USA
I	ANRS VAC 01	Completed	ALVAC vCP125	gp160 Vaccine (Immuno-AG)			Viral Vector - Pox, Protein	France
I	ANRS VAC 02	Completed	rgp 160 + peptide V3 ANRS VAC 02				Protein	France
I	ANRS VAC 03	Completed	ALVAC-HIV MN120TMG strain (vCP205)	CLTB-36 (gp24E-V3 MN)			Viral Vector - Pox, Protein	France

I	ANRS VAC 04	Completed	LIPO-6	Protein	France
I	ANRS VAC 04 bis	Completed	LIPO-6	Protein	France
I	ANRS VAC 05	Completed	ALVAC vCP125 ALVAC (vCP rage)	Viral Vector - Pox, Viral Vector - Pox	France
I	ANRS VAC 06	Completed	ALVAC vCP125 ALVAC (vCP rage)	Viral Vector - Pox, Viral Vector - Pox	France
I	ANRS VAC 07	Completed	ALVAC vCP300	Viral Vector - Pox	France
I	ANRS VAC 08	Completed	ALVAC-HIV MN120TMG strain (vCP205)	Viral Vector - Pox	France
